Beta-blockers for heart failure
36 results
1 - 36
Beta-blockers don't decrease mortality in patients with AF + CHF- Post-MI beta-blockers do not decrease mortality
- Perioperative beta-blockers = placebo for noncardiac surgery
- For patients with acute myocardial infarction and normal ejection fraction, beta-blockers did not improve cardiovascular outcomes (REBOOT-CNIC)
- Guideline for the management of heart failure: early prevention for patients at risk, quadruple therapy for those with symptoms
- No benefit of beta-blockers for patients following acute myocardial infarction with normal ejection fraction
- For patients with AMI and preserved ejection fraction, long-term beta-blockers do not improve outcomes (REDUCE-AMI)
- Low-dose digoxin and bisoprolol are equally beneficial for rate control/QOL in patients with CHF and permanent AF (RATE-AF)
- Diagnosing and managing acute heart failure Guidelines: NICE
- Continued beta-blocker use after acute myocardial infarction (AMI) reduces hospitalizations but not cardiovascular death, AMI, or stroke
- BNP monitoring + protocol improves HF outcomes
- SGLT2 inhibitors optimal drug class for heart failure with preserved and mildly reduced ejection fraction
- Eplerenone reduces mortality in NYHA II heart failure
- Digitoxin reduces composite of hospitalization for heart failure or all-cause mortality for patients with NYHA class III or IV heart failure (DIGIT-HF)
- BNP-guided therapy decreases heart failure mortality (BATTLESCARRED)
- Rhythm control improves quality of life in patients with CHF and AF
- CV interventions in old elderly are not useful (DEBATE)
- Beta-blockers associated with improved morbidity/mortality in COPD patients
- ACC/AHA guideline for the management of patients with chronic coronary disease
- In patients with heart failure with a preserved ejection fraction, tirzepatide reduces hospitalizations and the need for urgent therapy but not mortality
- Bedtime instead of morning ingestion of hypertension meds = significantly more reduction in cardiovascular disease risk
- ACE = ARB for secondary CV prevention; combination worse (ONTARGET)
- BNP-guided tx decreases CHF mortality
- JNC 8 report on prevention/evaluation/treatment of hypertension
- Lenient = strict rate control in prevention of adverse outcomes in AF
- Antihypertensive therapy beneficial for patients with BP < 140/90 and history of CVD
- Aficamten is more effective than metoprolol for improving symptoms of obstructive hypertrophic cardiomyopathy
- BP target of 120 no better than 140 in T2DM (ACCORD)